To prescribe codeine or not to prescribe codeine?

Area of Science:

Background:

Codeine-containing products are frequently prescribed for children (3-17 years) during emergency department (ED) visits, averaging 700,000 prescriptions annually over the past decade.
Despite American Academy of Pediatrics warnings in 1997 and 2006 regarding safety and effectiveness, codeine remains common for upper respiratory infections.
Potential shifts in prescribing patterns, including increased codeine use due to hydrocodone rescheduling, warrant a review of its risks.

Purpose of the Study:

To critically evaluate the safety and effectiveness of codeine-containing products in pediatric patients.
To highlight concerns regarding codeine use, particularly within the emergency department setting.
To inform prescribers about the risks associated with codeine, especially in light of evolving drug scheduling.

Main Methods:

Review of existing literature and guidelines concerning codeine use in pediatric populations.
Analysis of prescribing trends for codeine-containing products in association with emergency department visits.
Discussion of pharmacologic and safety considerations relevant to codeine in children.

Main Results:

An average of approximately 700,000 annual prescriptions for codeine products were issued to children aged 3-17 in conjunction with ED visits over the last decade.
Existing guidelines have previously raised concerns about the safety and efficacy of codeine.
Anticipated changes in the scheduling of other medications may inadvertently increase reliance on codeine.

Conclusions:

Codeine's continued widespread use in pediatric emergency care necessitates a thorough examination of its safety and effectiveness profile.
Prescribers should be aware of the potential risks and limited benefits of codeine in children.
Further consideration of alternative pain and cough management strategies is warranted for pediatric patients, especially in the ED setting.

Related Experiment Videos